Secondly, as eIF4E overexpression promotes the expression of ERα, with the increasing amount of ERα available in cells, the original tamoxifen dosage might become insufficient to suppress the ER-signalling pathway and inhibit cancer cell growth. The gene discussed is ESR1; the disease is cancer.